By Charlie Maher
Technology transfer is essential to advancing pharmaceutical products from development, through clinical and into commercial operation. The complexity of transferring the production of a product from a sending unit to the receiving unit is challenging even in the best of conditions. Since the onset of the COVID-19 pandemic the industry has shifted into high gear to develop, test and manufacture diagnostic tests, vaccines and therapies. With these developments, the speed, challenges and stakes involved in technology transfer have reached new heights.
Given these challenges, I recently presented a webinar highlighting technology transfer project management best practices in the era of COVID-19.
Following the webinar, I have received a number of questions. Responses to these questions are below.